ZELTIQ Aesthetics â€“Confidential and Proprietary 
Part Number: CS-302106 Revision: 02 Page 1 of 39
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242852]: Check with Document Control for current revisions of all referenced documents.
ZELTIQ P/N: CS-302106-02
Protocol Number: ZA18-[ADDRESS_294516]
Pleasanton, CA 9 4588
Protocol Number: ZA18-002
Protocol Version: 2.0
Protocol Date: February 19, [ADDRESS_294517]: ZELTIQ CoolSculptingÂ® System
Investigator/Co-
Investigator(s): Innovation Research Center
[ADDRESS_294518]
PH: 
Fax: CS-310562-01_Appendix A_Clinical Protocol _Feasibility Study of CS and RF for Submental, ZA18-002
1&71&7
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003]
[COMPANY_003]
CCI
CCI
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 4 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-002 
This document and the contents hereof are considered propr ietary and confidential information of ZELTIQ Aesthetics, Inc. 
Disclosure to unauthorized individuals  or dissemination, publication or copying is prohibited without prior written consent of 
ZELTIQ.   
INVESTIGATOR SIGNATURE [CONTACT_242866]18-002  
  I agree to:  
â€¢ Implement and conduct this study diligently and in  strict compliance with this 
protocol, GCP, and all applicable laws and regulations.  â€¢ Maintain all information supplied by [CONTACT_1034], ZELTIQ Aesthetics, an Allergan affiliate, in 
confidence and, when this information is submitted to an Ethics Committee (EC), or another group, it will be submitted with a designa tion that the material is confidential. 
 I have read this protocol in its entirety and I agree to all aspects.    __         _______________         _______________________                     _______________   
Investigator printed name                 [CONTACT_242867] 
 
   
         _         ___                         
Co- Investigator printed name          [CONTACT_242868]  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 5 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-[ADDRESS_294519] Eligibility ...................................................................................................... 13  
3.8. Informed Consent ...................................................................................................... 14  
3.9. Screening Procedures .............................................................................................. 14  
Screening Visit; Required; Day  -45 to Day 0 ................................................................................... ... 14  
3.10. Study Enrollment ....................................................................................................... 15  
3.11. Study Treatment Procedures ................................................................................... 16  
3.11.1.  Treatment Visit #1; Req uired: Day 0 ................................................................................. 16  
3.11.2.  Treatment Visit #2; Group B; Week [ADDRESS_294520]-Treatment #1 (Â± 2 weeks)  ........................... 17  
3.12. Follow-up Procedures ............................................................................................... 18  
3.12.1.  1-Week Follow-Up Visit; Requir ed: Day 7 (Â± 3 days) ....................................................... 18  
3.12.2.  12-Week Final Follow-Up Evaluation; Required (12 weeks Â± [ADDRESS_294521] final treatment)
 [ADDRESS_294522] Satisfaction...........................................................................................................  23 
3.14. Endpoints ................................................................................................................... 2 4 
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 6 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-002 
This document and the contents hereof are considered propr ietary and confidential information of ZELTIQ Aesthetics, Inc. 
Disclosure to unauthorized individuals  or dissemination, publication or copying is prohibited without prior written consent of 
ZELTIQ.  3.14.1.  Primary Endpoints .............................................................................................................  24 
3.14.2.  Secondary Endpoints ........................................................................................................ 24  
3.15. Statistical Analysis Plan ........................................................................................... 25  
3.15.1.  Statistical Methods: Ov erall Plan ...................................................................................... 25  
3.15.2.  Analysis Population ...........................................................................................................  25 
3.15.3.  Endpoint Analysis .............................................................................................................. 26  
Primary Safety Endpoint: ...................................................................................................... ......................... 26  
Primary Efficacy Endpoint: Investigator Graded Gl obal Aesthetic Improvement Scale (IGAIS) .................... 26  
3.16. Protocol Adherence .................................................................................................. 27  
3.17. Adverse Events ......................................................................................................... 27  
3.18. Reportable Incidents ................................................................................................. 29  
4. Study Management and Qu ality Control ............................................................ 30  
4.1. Study Data Collection ............................................................................................... 30  
4.2. Confidentiality ........................................................................................................... 30  
4.3. Investigator Responsibilities ................................................................................... 30  
4.3.1.  General Responsibilities ................................................................................................... 30  
4.3.2.  Investigator Records ......................................................................................................... 31 
4.3.3.  Investigator Reports ..........................................................................................................  32 
4.4. Sponsor Responsibilities ......................................................................................... 33  
4.4.1.  General Responsibilities ................................................................................................... 33  
4.4.2.  Training ...................................................................................................................... ....... 33  
4.4.3.  Monitoring .................................................................................................................... ..... 34  
4.4.4.  Final Report ....................................................................................................................... 35  
4.4.5.  Trial Registration ............................................................................................................ ... 35  
5. Data Ownership .................................................................................................... 35  
6. Publication P olicy ................................................................................................ 35  
7. Risk/Benefit Analysis ........................................................................................... 36  
7.1. Benefits ......................................................................................................................  36 
7.2. Risks ......................................................................................................................... .. 36 
8. References ............................................................................................................ 39  
 
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 7 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-002 
This document and the contents hereof are considered propr ietary and confidential information of ZELTIQ Aesthetics, Inc. 
Disclosure to unauthorized individuals  or dissemination, publication or copying is prohibited without prior written consent of 
ZELTIQ.  1. Protocol Summary 
 
Title Feasibility study to explore the safety and efficacy of cryolipolysis followed by 
[CONTACT_242854], randomized, interventional cohort 
Purpose The purpose of this study is to evaluate the safety and efficacy of sequential use of 
CoolSculpting  (Cryolipolysis) and radiofrequency treatment of the submental and 
submandibular area 
Enrollment Up to forty (40) subjects 
Clinical Site Up to three (3) investigational sites 
Subject 
Population Healthy adult men and women with skin fold thickness of > 1 cm in the submental 
and submandibular area who desire reducti on of submental and submandibular fat 
Primary 
Endpoint  Safety endpoint: Incidence of unanticipated ad verse device effects (UADE).  It is 
expected there will be zero UADEs.  
 
Efficacy Endpoint:  
Assessment of overall treatment outcome  in submental and submandibular area 
using Investigator-graded Global Aesthetic Improvement Scale (IGAIS) at 12-
weeks post final treatment.  
Secondary 
Endpoint  Efficacy Endpoints:  
1. Assessment of overall treatment outcome in submental and submandibular area 
using Subject-graded GAIS (SGAIS) administered at [ADDRESS_294523] Self-Rating Scale score ( SSRS). 
3. Subject satisfaction as assessed by [CONTACT_242855] 12- weeks post 
treatment.   
4. Reduction in fat layer thickness, as measured by [CONTACT_242856] [ADDRESS_294524] 
Pleasanton, CA [ZIP_CODE] 
  
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 8 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-[ADDRESS_294525] specific fat bulges but require significant fat reduction to achieve aesthetic results are candidates for invasive and minimally-invasive procedures, such as liposuction and laser-assisted liposuction. Although effective at reducing fat, these invasive and minimally-invasive procedures involve significant patient pain, expense, downtime, and the risks typi[INVESTIGATOR_229281]. As a result, patients who do not require significant fat reduction to achieve meaningful aesthetic results typi[INVESTIGATOR_229282]-invasive fat reduction and body contouring procedures to avoid the pain, expense, downtime, and surgical risks associated with invasive and minimally-invasive procedures.  ZELTIQ Aesthetics has developed and commercialized a technology to non-invasively reduce subcutaneous fat.  The ZELTIQ technology utilizes the sensitivity of fat cells to cold injury in order to selectively eliminate subcutaneous fat tissue without affecting the skin or other surrounding tissues. Termed cryolipolysis, this technology enables a non-invasive alternative for subcutaneous fat reduction through cellular apoptosis. The ZELTIQ CoolSculpting System, which is cleared for use in the [LOCATION_002] for an indication of fat layer reduction in the flanks, abdomen, thighs, bra fat, back fat, banana roll, upper arms, and submental and submandibular 
areas through cold-assisted lipolysis, has been clinically proven to reduce fat bulges, allowing 
patients to achieve noticeable and measurable aesthetic results without the pain, expense, downtime, and risks associated with existing invasive and minimally-invasive procedures.  
CCI
CCI
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 10 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242857]: Check with Document Co ntrol for current revisions of all referenced documents. 
 
 
ZELTIQ P/N: CS-302106-02 
Protocol Number: ZA18-002 
This document and the contents hereof are considered propr ietary and confidential information of ZELTIQ Aesthetics, Inc. 
Disclosure to unauthorized individuals  or dissemination, publication or copying is prohibited without prior written consent of 
ZELTIQ.  2.2. Device Description 
 
The CoolSculpting System is comprised of a control unit (Figure 3 ) which houses the system 
controller and power source, and detachable applicators such as the CoolMini ( Figure 4), that are 
used to apply the cooling and/or warming to the treatment site. The vacuum applicators use 
vacuum pressure to draw tissue into the cup shaped applicator. Tissue drawn into the cup will be treated using a cooling parameter of -11
â—¦C for up to 45 minutes. 
  
   
Figure 3.  CoolSculpting System Control Unit. 
 
 
 
Figure 4:  CoolMini Applicator. 

ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 11 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242858] P/N: CS-302106-02 
Protocol Number: ZA18-[ADDRESS_294526] 24, 2010 fo r â€œuse as a non-invasive 
dermatological aesthetic treatment to affect the appearance of flanksâ€ (DEN090002). On May 9, 
2012, the ZELTIQ System received market clearance for treatment of the abdomen (K120023); on April 9, 2014 the System received market clearance for treatment of the thighs (K133212); and on September 24, 2015 the System received market clearance for treatment of the submental area (K151179). Subsequently, the System received clearance for bra fat, back fat and banana roll (K160259), upper arms (K162050), the submandibular area (K181740), and can affect the appearance of lax tissue after submental treatment (K172144).  FDA clearance allows treatment duration of up to 120 minutes, and at temperatures as low as - 15á‚.    
 This study will investigate the use of the FDA-cleared ZELTIQ CoolSculpting System and the CoolMini vacuum applicator for treatment of subcutaneous fat in the submental and submandibular area followed by [CONTACT_242859]  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 12 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-002 
This document and the contents hereof are considered proprietary and confidential information of ZELTIQ Aesthetics, Inc. 
Disclosure to unauthorized individuals or dissemination, publication or copying is prohibited without prior written consent of 
ZELTIQ.  or 10-14 weeks later. Results from this clinical trial will be used to further support safety and 
efficacy of using the Zeltiq CoolSculpting System sequentially with radiofrequency for fat 
reduction/improved aesthetic outcome in the submental and submandibular areas. 
3. Study Protocol  
3.1. Design 
Prospective, randomized, interventional cohort. 
3.2. Study Duration  
Enrollment and follow-up is expected to take up to six (6) months for each subject. 
3.3. Physician Participants 
Study investigators must be practicing medical physicians with experience in the use of the ZELTIQ CoolSculpting System and radiofrequency energy device. 
3.4. Site Requirements 
Site investigators should have at least one study coordinator with experience in conducting clinical research and with sufficient time to conduct the study. 
3.5. Subject Recruitment 
Subjects who seek reduction of fat in the submental area and submandibular area will be recruited from the general population. CCI
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 13 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-002 
This document and the contents hereof are considered propr ietary and confidential information of ZELTIQ Aesthetics, Inc. 
Disclosure to unauthorized individuals  or dissemination, publication or copying is prohibited without prior written consent of 
ZELTIQ.  3.6. Sample Size 
A maximum of forty (40) subjects will be treated at up to three investigational sites. 
3.7. Subject Eligibility 
To be eligible to participate in the study, sub jects must meet all the inclusion criteria and 
none of the exclusion criteria listed in Table 1 . 
Table 1.  Eligibility criteria. 
Inclusion Criteria  
a) Male or female subjects â‰¥22 years of age and â‰¤ 65 years of age. 
b) Treatment area skin fold thickness > 1cm (measured by [CONTACT_4733]). 
c) Dissatisfaction with the treatment area expressed by [CONTACT_2180] a rating of 0, 
[ADDRESS_294527] Self Rating Scale (SSRS) as determined at Screening 
visit.  
d) No weight change exceeding 5% of body weight in the preceding month. 
e) Agreement to maintain his/her weight (i.e., within 5%) by [CONTACT_242860].  
f) Subject has signed a written informed consent form. 
Exclusion Criteria  
a) Body Mass Index â‰¥  46.2 as determined at screening. 
b) Excessive skin laxity in the treatment area for which reduction of subcutaneous 
fat may, in the opi[INVESTIGATOR_73829], result in an unacceptable aesthetic 
result.  
c) Prominent platysmal bands at rest which may interfere with a ssessment of 
treatment area. 
d) Evidence of any cause of enlargement in the treatment area other than localized 
subcutaneous fat, such as swollen lymph nodes or ptotic submandibular glands. 
e) Significant enlargement on the anterior neck that may prevent the proper 
placement of the applicator e.g. enlarged thyroid glands. 
f) Treatment with dermal fillers, chemical peels, radiofrequency or laser procedures 
that may affect contour in the treatment area within the past 6 months. 
g) Botulinum toxin, deoxycholic acid, or other aesthetic drug injections within the 
treatment area in the past 6 months. 
h) History of facial nerve paresis or pa ralysis (such as Bell's palsy).  
i) History of a fat reduction procedure (e. g., liposuction, surgery, lipolytic agents, 
etc.) or implant in or adjacent to the area of intended treatment. 
j) History of prior neck surgery, or prior surgery in the area of intended treatment. 
k) Current infection in and ad jacent to treatment area. 
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 14 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-002 
This document and the contents hereof are considered propr ietary and confidential information of ZELTIQ Aesthetics, Inc. 
Disclosure to unauthorized individuals  or dissemination, publication or copying is prohibited without prior written consent of 
ZELTIQ.  l) Known history of cryoglobulinemia, cold ur ticaria, cold agglutinin disease or 
paroxysmal cold hemoglobinuria. 
m) Known history of Raynaudâ€™s disease, or any known condition with a response to 
cold exposure that limits blood flow to the skin. 
n) History of bleeding disorder or is taking any medication that in the investigatorâ€™s 
opi[INVESTIGATOR_229283]â€™s risk of bruising.  
o) Currently taking or has taken diet pi[INVESTIGATOR_242850]. 
p) Any dermatological conditions, such as scar s in the location of the treatment area 
that may interfere with th e treatment or evaluation. 
q) Active implanted device such as a pacemaker, automatic implantable 
cardioverter/defibrillator (A ICD), drug delivery system, or any other implantable 
electrical device. 
r) Pregnant or intending to become pregnant in the next 6 months. 
s) Lactating or has been lactating in the past 6 months. 
t) Unable or unwilling to comply with the study requirements including remaining 
clean shaven for all study visits. 
u) Currently enrolled in a clinical study of an unapproved investigational drug or 
device. 
v) Any other condition or laboratory value th at would, in the professional opi[INVESTIGATOR_8574], potentially affect the s ubjectâ€™s response or the integrity of the 
data or would pose an unacceptable risk to the subject.  
3.8. Informed Consent  
Study candidates shall receive an explanation of the study objectives, possible risks and 
benefits of the study, and be given adequate time to read the information included in the 
informed consent document. Candidates will be given an opportunity to ask questions 
about any of the information contained in the informed consent. Candidates must verbally 
acknowledge understanding of the informed consent and sign the consent form accordingly. This form must have prior approval of the Institutional Review Board (IRB).  
3.9. Screening Procedures 
Screening Visit; Required; Day -[ADDRESS_294528] to confirm eligibility for 
the study. 
 
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 15 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-[ADDRESS_294529] Self-Rating Scale score.  
3. Visually assess and palpate the intended treatment area to determine if it is 
appropriate for treatment. 
4. Assess oral cavity for current dental infection or evidence of dry mouth.  
5. Assess function of the marginal mandibular  nerve (grimace with ability to show 
lower teeth) and hypoglossal nerve (tongue does not deviate upon protrusion).  
6. Assess upper neck to rule out enlarged lymph nodes or glands.  
7. Measure the skin fold thickness of the in tended treatment areas using a caliper. 
8. Assess for dermatological conditions or implantable devices that may lead to 
exclusion of a subject from the study. 
9. Document potential candidateâ€™s medication use (including over -the-counter 
medications, vitamins and herbs), Fitzpatrick Skin Type, race and ethnicity as well as any skin irregularities (e.g. moles, birth marks, scars, stretch marks, 
discoloration) at the intended treatment area.  
 
All female subjects of childbearing potential wi ll be assessed for the start date of their 
last menstrual cycle to determine if they may be pregnant.  If unsure, a pregnancy test (urine) may be taken at the screening visit.  If the subject is pregnant, she will be 
excluded from participation.  Subjects will al so be advised to a void becoming pregnant 
during the course of the study by [CONTACT_2329] a medically accepted form of contraception if 
they are sexually active.  If the subject becomes pregnant during the course of the study, 
she will not be treated subsequently with th e study device or be required to have follow-
up photographs taken.   
 
All subjects will be asked to maintain their weight by [CONTACT_242861].  If a subjectâ€™s weight change 
is more than 5% at 12 weeks after the final treatment, the subjectsâ€™ data will be excluded from the primary effectiveness analyses. S ubjects who do not maintain their weight 
within 5% will continue in the study, however their data will be excluded from efficacy analyses.   
 
Subjects who meet all of the inclusion criter ia and none of the exclusion criteria shall be 
eligible to participate in the study and the first treatment will be scheduled. 
3.10. Study Enrollment 
Study candidates who sign the informed consent and meet eligibility criteria a and desire to be in the study are considered enrolled. 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 25 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-[ADDRESS_294530]-final 
treatment.   
 
3.15. Statistical Analysis Plan 
3.15.1. Statistical Methods: Overall Plan 
Data will be summarized based on the n ature of the data.  Dichotomous (e.g., 
gender, independent photographic review ) and ordinal (e.g., Fitzpatrick Skin 
type) data will be tabulated by [CONTACT_17203].  The mean, standard error, 
maximum and minimum will be tabulat ed for continuous data (e.g., age,).  
The significance level will be two-sided 0.05 for all statistical tests.  
3.15.2. Analysis Population 
Analysis Populations are defined as following: 
Per-protocol Population (PP): 
The Per-protocol Population will consist of all treated subjects followed for 
[ADDRESS_294531] the images, the primary 
efficacy analysis will be performed based on this study population. Subjects 
who do not complete treatment will not be included in the primary and 
secondary efficacy analyses. 
 
As-Treated Population (AT): 
This population consists of all treated subjects regardless of whether they 
become pregnant or undergo weight change during the study.   
 
Safety Population (SA): 
This population will consist of all treated subjects with safety evaluation after 
the treatment.  This population should be identical to the AT population.  The safety data analyses will be per formed based on the Safety Population. 
 
Sample Size Requirement 
CCI
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 27 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-[ADDRESS_294532] (e.g., enrollment of a subject who does not meet the study criteria).  Or, non-adherence to Good Clinical Practices (GCP) that may impact patient safety (e.g., failure to obtain proper consent prior to performing study procedures).  Violations should be reported to the study Sponsor and the IRB within [ADDRESS_294533] (e.g., subject missed visit).  Protocol deviations are not required to be reported to the IRB; however, they must be recorded on the study case report forms and may be reported and reviewed in conjunction with the progress report as part of the annual review process. 
3.17. Adverse Events 
Adverse events (AE) will be assessed continuously throughout the study. An adverse event is defined as any untoward medical occurrence in a subject, regardless of whether the event is related to the device.  CCI
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 28 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-[ADDRESS_294534] (ADE)  Any sign, symptom, or disease in a study subject that occurs during the course of a clinical trial that is determined by [CONTACT_8127] a causal relationship or possible causal relationship with the device under investigation. 
 Device Deficiencies  A device deficiency is defined in accordance with ISO [ADDRESS_294535] to its identity, quality, durability, reliability, safety, 
or performance. Device deficiencies include  malfunctions, use errors, and inadequate 
labeling.  If a device deficiency occurs, the investigati onal site will document the event using the 
CRF. Device deficiencies will be documented throughout the study and appropriately managed and reported to regulatory authorities and IRBs as required by [CONTACT_94097].  
Serious Adverse Event (SAE) 
 Any untoward medical occurrence in a subject,  regardless of whether the event is related 
to the device that:  a. results in death; 
b. results in a life-threatening illness or injury; 
c. results in a permanent impairment of a body structure or body function;  
d. requires in-patient hospi[INVESTIGATOR_1081] 
e. results in medical or surgical intervention to prevent impairment to body structure or function; 
f.    results in fetal distress, fetal death, or a congenital abnormality/birth defect. 
 
Unanticipated Adverse Device Effect (UADE)  
Any serious adverse effect on health and saf ety or any life-threatening problem or death 
caused by, or associated with a device, if that effect, problem, or death was not 
previously identified in nature, severity, or de gree of incidence in the investigational plan 
or application, or any other unanticipated seri ous problem associated with a device that 
relates to the rights, safety, or welfare of subjects.  
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 29 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-002 
This document and the contents hereof are considered propr ietary and confidential information of ZELTIQ Aesthetics, Inc. 
Disclosure to unauthorized individuals  or dissemination, publication or copying is prohibited without prior written consent of 
ZELTIQ.   
The Investigator shall be responsible for determination of the causal relationship of all 
adverse events to the device and/or procedure .  The Principal Investigator [INVESTIGATOR_242851].    The Sponsor is responsible for the ongoing safety evaluation of the product(s). The 
Sponsor shall be responsible for adjudication of  all reported adverse events to determine 
whether the event is reportable under fe deral regulations (i.e., 21 CFR812.150[b][1]). The 
Sponsor will promptly notify all participating investigators and regulatory authorities, as appropriate, of findings that could affect a dversely the safety of subjects, impact the 
conduct of the trial or alter the IRBâ€™s approval opi[INVESTIGATOR_150831].  
 
3.18. Reportable Incidents 
Serious adverse events (SAEs) and unanticip ated adverse device effects (UADEs) must 
be recorded and reported to the manufacture r of the study device and to the Sponsor or 
designee within [ADDRESS_294536] 
Pleasanton, CA [ZIP_CODE] 
 (cell) 
 (office) 
 (fax) 
 
A full reporting of the event shall be provided within [ADDRESS_294537].  
Additional information obtained by [CONTACT_242862], both 
serious and non-serious, will be reported to the Sponsor within 24 hours of awareness.  
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 30 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-002 
This document and the contents hereof are considered propr ietary and confidential information of ZELTIQ Aesthetics, Inc. 
Disclosure to unauthorized individuals  or dissemination, publication or copying is prohibited without prior written consent of 
ZELTIQ.  4. Study Management and Quality Control  
4.1. Study Data Collection   
Standardized Case Report Forms (CRFs) will be provided to all participating sites.  Data 
will be reviewed by [CONTACT_242863]. 
4.2. Confidentiality 
All information and data concerning study subjec ts will be considered confidential, and 
handled in compliance with all applicable re gulations including the requirements of the 
Health Insurance Portability and Accountability Act (HIPAA) of 1996.  
Only authorized site staff, the study Sponsor or the Sponsorâ€™s designee and IRB will have 
access to these confidential files. A unique identification code will be assigned to each subject participating in this trial. All data used in the analysis, reporting and publication of this clinical trial will be maintained without  identifiable reference to the subject. Any 
data that may be published in abstracts, s cientific journals, or presented at medical 
meetings will reference a unique subject co de and will not reveal the subjectâ€™s identity.  
4.3. Investigator Responsibilities 
4.3.1. General Responsibilities   
Investigators are responsible for ensuring the investigation is conducted 
according to all signed agreements, the Investigational Plan, and applicable 
regulations.  The investigator must protect the rights, safety, privacy and welfare of the subjects under the Investigatorâ€™s care. Investigators will assume overall responsibility and accountability for study site staff and for the clinical data obtained during the study.  The investigator assumes all responsibilities per applicable regulations, including but not limited to: 
IRB Approval  
The investigator may not begin the study until the governing institutional 
review board (IRB) provides written approval of the study protocol and consent form.  The investigator is also responsible for fulfilling any conditions of approval imposed by [CONTACT_1201].
 
Informed Consent  
The investigator must ensure that informed consent is obtained from each prospective study subject and that the study is not commenced until IRB approval has been obtained.   
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 31 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-[ADDRESS_294538] be retained for a period of two years followi ng (1) the date the investigation was 
completed or terminated, or (2) the records are no longer required to support a regulatory submission or completion of a product development protocol, whichever is longer.  Participating investigators shall maintain the following:  
x All correspondence with the Sponsor, another investigator, the IRB, and a monitor 
x Records of all persons authorized to conduct the study (e.g. 
Delegation of Duties/Sign ature Authorization, CV) 
x Records of receipt, use or disposition of the device 
x Informed Consent documentation for all enrolled subjects 
x Records of each subject's case history, including study-required Case Report Forms and source documentation (e.g. physician notes, lab 
reports, study worksheets, clinic charts) 
x All relevant observations of adverse device effects 
x Records of any protocol deviations 
x The condition of each subject upon entering and during the course of the investigation and any relevant medical history and results of any diagnostic tests 
x Record of each subjectâ€™s exposure to the device , including the date 
and time of use 
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 32 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-[ADDRESS_294539] be available and suitable for inspection at any time by 
[CONTACT_56509] (monitor), or  the reviewing IRB. The Investigator 
will supply access to study-related medi cal records, original laboratory data, 
and other records and data as they relate to  the trial.  The investigator will 
ensure that both he/she and his/her study staff have adequate time and 
resources to devote to the study, including study enrollment, subject evaluations, study documenta tion and site monitoring. 
4.3.3. Investigator Reports 
The investigator is responsible for preparation and submission of the following reports: 
x Report of any unanticipated adverse device effects shall be submitted 
to the Sponsor within [ADDRESS_294540]. 
x Withdrawal of IRB approval of the investigatorâ€™s part in the 
investigation shall be reported to the Sponsor within [ADDRESS_294541] 
shall be reported to the Sponsor and IRB within 5 working days after 
the use occurs. 
A final report shall be submitted to  the Sponsor and IRB within 3 months 
after termination or completion of the i nvestigation, or the investigatorâ€™s part  
of the investigation. 
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 33 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-[ADDRESS_294542] of 
the study including assurance that the study satisfies FDA regulatory requirements. ZELTIQ assumes all responsibilities per applicable regulations, and shall: 
IRB approval Ensure IRB approval for the investigation. Ensure IRB approval for a 
supplemental application before beginning that portion of the investigation.  
Investigators 
Select investigators qualified by [CONTACT_242864], and providing them 
with the information they need to con duct the investigation properly.  Obtain 
a signed Investigator Agreement from each participating investigator. Study 
sites will be evaluated to ensure that th ey have an adequate subject base and 
can provide sufficient staff and documentation support to conduct the study properly. 
Monitoring  
Select monitors qualified by [CONTACT_45437] a nd experience to monitoring the study 
and ensure proper monitori ng of the investigation. 
Investigational devices  
Not applicable. This is a non-significant risk study Data Management and Analysis  
 
Ensure data collection, verification, an alysis, records storage, etc. Sponsor  
will assist with presentation(s) and/or publication(s). 
4.4.2. Training 
Study Training 
To ensure uniform data collecti on and protocol compliance, Sponsor 
personnel will provide an educational session to study site personnel as 
needed, which will cover the protocol, techniques for the identification of 
eligible subjects, data collection and form completion, and the device 
directions for use.  The investigator and study staff will be trained on the 
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 34 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-[ADDRESS_294543] of the tr ial and that monitoring is performed 
in accordance with the Sponsorâ€™s approved procedures or third-party 
procedures approved by [CONTACT_1034].  
The clinical monitors will evaluate compliance with the protocol, any 
specific recommendations made by [CONTACT_779]â€™ s IRB and the signed Investigator 
Agreement.   Site Qualification Visit A pre- study meeting will occur with the study site to evaluate the siteâ€™s 
qualification to conduct the study.  
Monitoring Visits 
On-site monitoring visits will asse ss the progress of the clinical study and 
identify any concerns that result from device performance or review of the 
investigatorâ€™s study records, study management documents, and informed consent documents.   
Monitoring will ensure continued protocol compliance, accurate data 
reporting, and adequate accounting of shipments of study devices. Monitoring visits will occur after enrollment of every [ADDRESS_294544] records and other 
supporting documents with reports at the site to determine that: 
x The facilities used by [CONTACT_242865]. 
x Informed consent was properly obtained and documented for all enrolled study participants. 
x The Investigational Plan is being followed, and only eligible subjects 
are being enrolled into the study. 
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 35 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-[ADDRESS_294545] site close 
out per Sponsorâ€™s standard procedure.  
4.4.4. Final Report  
A final report will be prepared at the conclusion of the trial. A copy of the final report will be provided to each investigator and to the respective IRBs. 
4.4.5. Trial Registration  
Prior to study initiation, the trial will be registered on a publicly accessible 
study database such as clinicaltrials.gov when applicable. 
5. Data Ownership  
ZELTIQ, the study Sponsor, retains ownership of all data generated in this study, and controls 
the use of the data for purposes of regulatory submissions to the US and/or other governments. Investigator(s) and institution(s) (which shall include their employees, agents, and representatives) may not issue or disseminate any press release or statement, nor initiate any communication of information regarding this study (written or oral) to the communications media or third parties without the prior written consent of the Sponsor.  
CCI
CCI
CCI
CCI
ZELTIQ Aesthetics  â€“ Confidential and Proprietary    
Part Number: CS-302106  Revision: 02  Page 39 of 39  
Title: Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis 
Followed by [CONTACT_242853] P/N: CS-302106-02 
Protocol Number: ZA18-002 
This document and the contents hereof are considered propr ietary and confidential information of ZELTIQ Aesthetics, Inc. 
Disclosure to unauthorized individuals  or dissemination, publication or copying is prohibited without prior written consent of 
ZELTIQ.  8. References  
1. Kilmer, S. L, Burns, A. J., Zelickson, B. D. (2016). Safety and Efficacy of Cryolipolysis 
for Non-Invasive Reduction of Submental Fat. Lasers Surg Med. 48 (1), 3-13.  
2. Bernstein, E. F. & Bloom, J. D. (2017). Safety and Efficacy of Bilateral Submental Cryolipolysis with Quantified Three-Dimensional Imaging of Fat Reduction and Skin Tightening. JAMA Facial Plastic Surgery. April 2017.  
3. Suh, D. H., Park, J. H., Jung, H. K., et al. (2017). Cryolipolysis for submental fat 
reduction in Asians. Journal of Cosmetic and Laser Therapy .  
4. Fitzpatrick R, Geronemus R, Goldberg D, Kaminer M, et al. Multicenter study of noninvasive radiofrequency for periorbital tissue tightening.  Lasers Surg Med. 
2003;33:232-42. 
5. Carruthers J, Fabi S, Weiss R.  Monopolar Radiofrequency for Skin Tightening: Our Experience and a Review of the Literature.  Dermatol Surg.  2014;40:S168-S173. 
Signature:
[INVESTIGATOR_49852]:
[COMPANY_003]
 		

 

 
 
	 


 

" 
)

*"&
 +, -.),/0
12%[ZIP_CODE]-
89:;<,+=6
? 		

 ? .
"
,&'
 &

 $
   9@ A@*
,&'
 
'

  B "
)
   9@ A@*
7'
 %
C
 $
  3 9@ A@*


&
 C
 $
 &$ 
)!
  83 9@ A@*
,&'
 
"
)
 $

)
) 
" 9
	
 

)
 ,
   83 9@ A@*  *
'
 &
 "
% 

)

'
 &'	

!
  83 9@ A@*
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]